Artelo Biosciences (ARTL) CFO receives 36,391 options vesting over 4 years

Rhea-AI Filing Summary

ARTELO BIOSCIENCES, INC. reported that its Chief Financial Officer, Mark Edward Spring, received a grant of stock options on January 29, 2026. The grant covers 36,391 stock options with an exercise price of $1.68 per share.

These options vest over four years, starting from a vesting commencement date of January 1, 2026. One forty-eighth of the option shares vests each month, so the award becomes fully vested on the four-year anniversary of that commencement date, as long as he continues as a service provider.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Spring Mark Edward

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	36,391	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 36,391 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spring Mark Edward

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.68	01/29/2026		A		36,391		(1)	01/29/2036	Common Stock	36,391	$0.00	36,391	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date, such that the option shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026.

Remarks:

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ARTL disclose about its CFO’s equity compensation?

ARTELO BIOSCIENCES, INC. disclosed that Chief Financial Officer Mark Edward Spring received stock options for 36,391 shares. These options were granted on January 29, 2026 and provide him the right to buy company common stock at a fixed exercise price of $1.68 per share.

How many stock options were granted to the ARTL CFO?

The Chief Financial Officer of ARTELO BIOSCIENCES, INC. was granted 36,391 stock options. Each option represents the right to purchase one share of common stock, subject to the vesting schedule and continued service conditions described in the company’s equity incentive plan footnote.

What is the exercise price of the ARTL CFO’s stock options?

The stock options granted to ARTELO BIOSCIENCES, INC.’s Chief Financial Officer carry an exercise price of $1.68 per share. This means he can purchase each underlying share of common stock at $1.68 once the corresponding option portion has vested and remains outstanding.

When do the ARTL CFO’s stock options start vesting?

The vesting of the ARTELO BIOSCIENCES, INC. CFO’s stock options is based on a vesting commencement date of January 1, 2026. Although the grant was dated January 29, 2026, all vesting calculations reference that January 1, 2026 commencement date under the company’s 2018 Equity Incentive Plan.

How does the vesting schedule work for the ARTL CFO’s options?

The vesting schedule provides that one forty-eighth of the 36,391 option shares vests each month after the January 1, 2026 vesting commencement date. This monthly vesting continues so that the entire option award becomes fully vested on the four-year anniversary of that commencement date.

What condition must be met for the ARTL CFO’s options to vest?

For each monthly vesting installment to occur, the reporting person must continue to be a “Service Provider” as defined in ARTELO BIOSCIENCES, INC.’s 2018 Equity Incentive Plan. If that service relationship ends, remaining unvested option shares would not vest under the described schedule.

How many derivative securities does the ARTL CFO hold after this grant?

After this grant, the ARTELO BIOSCIENCES, INC. Chief Financial Officer beneficially owns 36,391 derivative securities in the form of stock options. All of these options are reported as directly held and relate to an equal number of shares of the company’s common stock, subject to vesting terms.